TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05999760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge
Description: Evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge
Description: Evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chewing efficiency by electromyograph(E.M.G)
Description: Evaluation of chewing efficiency of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chewing efficiency by electromyograph(E.M.G)
Description: Evaluation of chewing efficiency of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
Study: NCT05787704

Intervention type: OTHER
Intervention: No intervention
Description: Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)
Study: NCT05888896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methyldopa tablets 250mg
Description: patients will be taken methyldopa tablets 250mg in the morning orally with a lot of water after breakfast daily and this medication continues for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methyldopa tablets 250mg + foot reflexology
Description: patients will receive methyldopa tablets 250mg in oral way once daily per 8 weeks and patients will receive foot reflexology two sessions per week, every session will last for 30 minutes and sessions will last for 8 weeks.
Study: NCT04844489

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
Description: Blood samples at:~* D0 (the day of the injection of the SARS-CoV-2 vaccine),~* during the 2nd injection as part of the national vaccination campaign (on D28)~* during the 3rd injection for patients for whom a third injection is recommended (according to the recommendations in force)~* then to M1, M6 and M12 of the last injection
Study: NCT05757765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deprescribing pharmacotherapy approach (DPA)
Description: A new way of medication review in patients with sarcopenia. This method is based on previous scientific research and is aimed at minimizing pharmacotherapy. The aim is to combat symptoms and complaints and to stop (preventive) medication as much as possible

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STOPP-START deprescribing approach (SSA)
Description: The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
Study: NCT06331247

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General dietary advice
Description: General dietary advice according to the Chinese Dietary Guidelines 2022.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General dietary advice
Description: General dietary advice according to the Chinese Dietary Guidelines 2022.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Localized MIND diet intervention
Description: The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
Study: NCT05999760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: masticatory performance(questionnaire)
Description: Evaluation of masticatory performance of Versacryle and CAD/CAM partial dentures by questionnaire on day one, on first month, and on the second month of prosthesis delivery.
Study: NCT06331247

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care and follow-ups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care and follow-ups.
Study: NCT04847323

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-bend Bonded Retainer
Description: Traditional stainless steel retainer commonly bonded in the anterior teeth of the mandibular arch to maintain their alignment after orthodontic treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum-formed Retainer
Description: Removable retainers made of plastic and derivatives. Currently gaining popularity due to the increased use of esthetic aligners. These clear retainers have the objective to maintain stable the results obtained after orthodontic treatment. They cover all the surfaces of the teeth up to the first or second molars.
Study: NCT05533060

Intervention type: OTHER
Intervention: No intervention
Description: patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected

Intervention type: OTHER
Intervention: No intervention
Description: patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
Study: NCT06036446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
Study: NCT05865184

Intervention type: OTHER
Intervention: Data collection
Description: Data collection of clinically relevant signals using home-based sensor system
Study: NCT05548036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPEP
Description: OPEP (Aerobika (tm)
Study: NCT05675735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Level Multidimensional Intervention
Description: The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Level Multidimensional Intervention
Description: The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Level Multidimensional Intervention
Description: The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Level Multidimensional Intervention
Description: The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Level Multidimensional Intervention
Description: The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Level Multidimensional Intervention
Description: The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.
Study: NCT06036446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Suppository Progesterone
Description: Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.

Intervention type: DRUG
Group type: OTHER
Intervention: Vaginal Suppository Progesterone
Description: Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
Study: NCT05599477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic sutured gastroplasty with endomina
Description: The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach
Study: NCT04248959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: Multimodal Prehabilitation~* Aerobic exercise~  * Home-based, high-intensity interval training (HIIT), 2 days/week~ * Home-based, moderate-intensity continuous training (MICT), 2-3 days/week~* Resistance exercise~  * Home-based, moderate-intensity resistance training, 2-3 d/wk, all major muscle groups (working around tumour-related deficits), 8-10 exercises, 12-15 repetitions, resistance bands and body weight based~* Nutrition~  * Protein intake 1.2-1.5 g/kg body weight/day in compliance with European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines~* Stress management~  * Daily mindfulness practice, 20 min/session, guided by audio file created at Mount Sinai Hospital
Study: NCT04903821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080
Description: Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080
Description: Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080
Description: Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080
Description: Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
Study: NCT06162390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients.
Study: NCT05427877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating device (Heatwave Technology)
Description: Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
Study: NCT05503667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furmonertinib
Description: Furmonertinib 80 mg/day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80 mg/day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 400 mg/4 weeks i.v. for 4 times
Study: NCT05855161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound therapy
Description: Participants will receive exercise-based training on a trampoline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises on a stable surface
Description: Participants will receive exercise-based training on a stable surface
Study: NCT04705844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
Study: NCT05146102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ethics communication in group, in line with the one to five-step method
Description: Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month.
Study: NCT05981989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural electrical stimulation (EES)
Description: Subjects will undergo a surgical procedure to implant a system that provides epidural electrical stimulation (EES) of the cervical spinal cord. After surgery, subjects will undergo a structured physical rehabilitation program and electrical stimulation.
Study: NCT04808557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biorepair Total Protection
Description: Volunteers will use Biorepair Total Protection for home oral hygiene for the following 30 days from the bonding procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne Repair & Protect
Description: Volunteers will use Sensodyne Repair \& Protect for home oral hygiene for the following 30 days from the bonding procedure.
Study: NCT05633745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEU-723
Description: Oral Doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Doses
Study: NCT05309876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle tool
Description: Regular use of the digital Lifestyle tool
Study: NCT05055245

Intervention type: OTHER
Intervention: cycles
Description: Patients are grouped according to the number of IVF/ICSI cycles.
Study: NCT05337033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-001
Description: CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol.
Study: NCT05606003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Level Multi-Component Intervention (MLI)
Description: The strategic components of our multi-level, multi-component intervention (MLI) include: 1. Building testing access for vulnerable populations, 2) Community Health Worker (CHW)-delivered navigation to SARSCoV- 2 testing and access and reinforce risk mitigation recommendations, 3) 2-1-1 helpline-referrals and navigation to FDA approved SARSCoV- 2 testing (and self sampling once approved) and risk mitigation education, and 4) social marketing and small media campaign to provide geo-targeted messages promoting testing and COVID risk mitigation behaviors. We selected these components because of their evidence base, their current use by partners in response to COVID 19, and confidence that they can be adapted through a community engaged process as described.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Just-In-Time Adaptive Intervention (Community JITAI)
Description: This intervention includes the same MLI components described above, with an added JITAI approach. Community and stakeholder partners will use real-time data related to testing and other relevant information generated by the Epidemiologic Surveillance and Analysis team (ESA) in Aim 1, as well as other information based on their community and stakeholder experience and tacit knowledge about factors influencing testing determinants, to adapt intervention activities as needed to optimize access to testing.
Study: NCT05397704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain pulse oximeter
Description: brain oxygen monitoring during hypoxia
Study: NCT06436664

Intervention type: OTHER
Group type: OTHER
Intervention: Tooth brushing
Description: Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth brushing
Description: Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth brushing
Description: Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth brushing
Description: Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.
Study: NCT06185270

Intervention type: DIAGNOSTIC_TEST
Intervention: SPPB
Description: Short Physical Performance Battery using the automated device (Andantefit)
Study: NCT05491460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5 MG Tab
Description: oral intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran 150 MG Tab
Description: oral intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban 60Mg Tab
Description: oral intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Tab
Description: oral intake